Incyte is a publicly traded biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology and inflammation/autoimmunity. The company is headquartered in Wilmington, Delaware, and was founded in 1991. Incyte markets Jakafi (ruxolitinib) in the United States and has a broader pipeline of medicines and clinical programs across hematologic cancers, solid tumors, and inflammatory diseases. For 2023, Incyte reported total revenues of approximately $3.7 billion. The company employs roughly 2,600 people.
Verified Email Pattern
{f}{last}@incyte.com
s****@incyte.com
s****@incyte.com
Find a verified email at Incyte
Look up any prospect by name, or by name and company, across 110M contacts.
Employees Directory
Showing 7 of 127 employees with verified contact records
| Name | Location | Verified Email |
|---|---|---|
|
Stephen Grim
Professional at Incyte
|
|
s****@incyte.com
|
|
Sue Carnes
Senior Manager
|
|
s****@incyte.com
|
|
Tammi Karasewski
Professional at Incyte
|
|
t****@incyte.com
|
|
Thao Tran Lapaire
Project Manager
|
|
t****@incyte.com
|
|
Vanessa Nkembi (Consultant)
Consultant
|
|
v****@incyte.com
|
|
Virginia Sala
Professional at Incyte
|
|
v****@incyte.com
|
|
Viviana Parravicini
Specialist
|
|
v****@incyte.com
|
Protected by reCAPTCHA. Google Privacy Policy and Terms of Service apply.